Market Place
Sourcing Support
HanAll Biopharma Reports Q3 2024 Results & Business Update
01 Nov 2024 //
PR NEWSWIRE
HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update
26 Jul 2024 //
PR NEWSWIRE
HanAll Biopharma Appoints Christopher as Chief Business Development
15 Jul 2024 //
PR NEWSWIRE
HanAll Biopharma: Turn Bio Deal For Novel Eye, Ear Disease Treatments
28 May 2024 //
PR NEWSWIRE
HanAll Initiates Phase 3 VELOS-4 Trial Of Tanfanercept In Dry Eye
03 May 2024 //
PR NEWSWIRE
HanAll Reports Q1 2024 Financials, Provides Business Update
30 Apr 2024 //
PR NEWSWIRE
HanAll Biopharma Reports FY 2023 Financial Results and Provides Business Update
21 Mar 2024 //
PR NEWSWIRE
HanAll, Daewoong and NurrOn to Showcase Ongoing Parkinson`s Disease Program
20 Dec 2023 //
PR NEWSWIRE
NurrOn Pharma Incorporated Appoints Dr. Almira Chabi to Board of Directors
11 Dec 2023 //
PR NEWSWIRE
HanAll Biopharma Reports Third Quarter 2023 Financial Results
26 Oct 2023 //
PR NEWSWIRE
Daewoong Pharma and NurrOn Pharmaceuticals Initiate Phase 1 Study of HL192
12 Oct 2023 //
PR NEWSWIRE
HanAll Biopharma Reports Second Quarter 2023 Financial Results
27 Jul 2023 //
PR NEWSWIRE
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences
12 Jun 2023 //
PR NEWSWIRE
HanAll Bio Announces Results from VELOS-3 Trial Evaluating Tanfanercept 0.25%
19 May 2023 //
PR NEWSWIRE
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth
29 Mar 2023 //
PR NEWSWIRE
HanAll Opens Applications for the 2023 Pharma Industry Fellowship Program
15 Mar 2023 //
PR NEWSWIRE
HanAll`s Partner Announces Positive Phase 3 Results for Batoclimab
06 Mar 2023 //
PR NEWSWIRE
Korea`s HanAll Biopharma invests in American biotech startup Interon
14 Feb 2023 //
BIOSPECTRUM ASIA
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
10 Feb 2023 //
PR NEWSWIRE
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
01 Feb 2023 //
PR NEWSWIRE
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update
15 Nov 2022 //
PRNEWSWIRE
HanAll`s Licensed Partner Enters Agreement with CSPC for Batoclimab
11 Oct 2022 //
PRNEWSWIRE
HanAll`s FcRn Inhibitor HL161ANS to be Added to the Development Program
04 Oct 2022 //
PRNEWSWIRE
HanAll Biopharma Reports Q2 2022 Results and Provides Business Update
29 Jul 2022 //
PRNEWSWIRE
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies
12 Apr 2022 //
PRNEWSWIRE
HanAll Biopharma Appoints Almira Chabi as CMO & CDO
21 Feb 2022 //
PRNEWSWIRE
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update
20 Jan 2022 //
PRNEWSWIRE
HanAll Biopharma Reports Third Quarter 2021 Results
28 Oct 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.